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Breast cancer is the most common cancer aﬀecting women globally. This paper discusses the current progress in breast cancer in
Westerncountries andfocuses onimportantdiﬀerences ofthisdiseasein low-andmiddle-incomecountries (LMCs).Itintroduces
several arguments for applying caution before globalizing some of the US-adopted practices in the screening and management of
thedisease.Finally,itsuggeststhatstudiesofbreastcancerinLMCsmightoﬀerimportantinsightsforamoreeﬀectivemanagement
of the problem both in developing as well as developed countries.
1.Introduction
Breast cancer is the most common cancer aﬀecting women.
Globally,about1.4million new casesarediagnosed each year
[1]. Breast cancer incidence varies considerably throughout
the world; age-standardized incidence is about 4-fold higher
in high-income countries in North America and Western
Europe compared to countries with the lowest per capita
income [2]. A strong correlation between age-standardized
incidence of breast cancer and the average gross domestic
product per capita can be demonstrated [3]. However, in
many low- and middle-income countries (LMCs), incidence
is increasing at a faster pace than in developed countries,
where the incidence is already high [4].
Several hypotheses for this rapid raise have been pro-
posed. The most common explanation regards the rapid
spreadingof“westernization”ofdietandlifestyle[4],charac-
terized by switching to foods that have a high-energy density
while decreasing physical activity, resulting in higher rates of
obesity. Diet changes may also result in loss of protective fac-
tors associated with traditional diets. For example, western-
ization of diet in Japan and Japanese immigrants to the US
is associated with marked increase of breast cancer incidence
and mortality [5]. Changes in women’s reproductive pat-
terns, often as a result of improved socioeconomic condi-
tions,includetheoccurrenceofearliermenarcheanddelayed
or reduced parity, each recognized as additional risk factors
of breast cancer [6]. Breast cancer in Singapore’s women
exempliﬁes the impact of these changes as their incidence of
breast cancer is rapidly approaching that seen in Europe [7],
a worrisome sign ofthe looming epidemicofbreast cancerin
other rapidly developing countries such as China and India.
In addition, longer lifespan, better policies for reporting dis-
ease diagnosis and the introduction of screening, at least
in some countries, all contributed to the increasing breast
cancer incidence in LMCs.
2.DifferencesinEpidemiologyand
ClinicalPresentationofBreast
CancerinLow-IncomeCountries:
The Exampleof Sub-SaharanAfrica
Breast cancer in LMCs diﬀers both in incidence and clinical
presentation from its counterpart in Western countries. Pro-
tective factors like delayed menarche, early- and multiparity,2 International Journal of Breast Cancer
and protracted breast-feeding all contribute to reduce the
risk of breast cancer in LMC, as demonstrated by its lower
incidence in Africa [8].
Nevertheless, breast cancer is the second most common
cancer among women in Sub-Saharan Africa, accounting for
16.8percentofallfemalecancers:anestimatedtotalof48,600
cases occurred in Sub-Saharan Africa in 2002 [9].
Noticeably,while lessfrequent,itismorefatal thanbreast
cancer in Western countries. The analogy with breast cancer
in African American women, also less frequent in incidence
and more fatal, has led to the hypothesis that inherited
factors associated with African heritage could contribute
to this outcome. Since most of the colonial slave trade
involved Sub-Saharan populations, Fregene and Newman
[10] reviewed the published information to explore corre-
lations between the characteristics of breast cancer in Sub-
Saharan Africa and in the United States, among women of
African American descent [11]. Despite the existing barriers
to obtain accurate information in countries without a well-
organized tumor registry system, consistent descriptors of
Sub-Saharan breast cancer emerged from this analysis: a
typical incidence between 35–45, later clinical stage, and
highermortality. While a complete histopathological charac-
terization of these tumors is often lacking because of limited
health care resources, Ikpatt et al. examined several hundred
breast cancerspecimens from Nigeria and compared themto
tumors from Finnish women: a pattern of higher prolifera-
tiverate,necrosis,andnuclearatypiawasdetectedamongthe
Nigerian specimens [12]. Similar conclusions were reached
in a review by Ly et al., who noticed that reported tumors
were mostly invasive ductal carcinomas with aggressive char-
acteristics: grade III histoprognosis, absence of hormonal
receptors, or HER2 expression, with nearly half of these tu-
m o r sc l a s s i ﬁ a b l ea st r i p l en e g a t i v e[ 13].
Among 1255 breast cancer women treated between 1999
and 2006 at Gezira University in Central Sudan, 74% were
premenopausalatthetimeofdiseasepresentation,whichwas
predominantly at stages III and IV (60.7%). Among the few
patients whose tumor specimens had undergone assessment
of hormonal receptors expression, only in 20% of the cases,
t h e yw e r ef o u n dt ob ep o s i t i v e[ 14]. A similarly low rate of
ER/PR positive tumors was found in a study of breast cancer
patients diagnosed in Nigeria [15].
A recent report analyzing 57 breast cancer specimens
from Ocean Road Cancer Institute (ORCI) in Dar es Salam
found ER-PR-histology in 49%. The same study reported
that 90.7% of the 356 patients staged presented with stages
III and IV disease [16].
While sociocultural factors are likely to underlie delay in
diagnosis,someevidencealsosuggestsamorerapidcourseof
the disease in these populations, associated with the preva-
lence of a more aggressive breast cancer phenotype, as
conﬁrmedbyamorefrequentincidenceofthetriplenegative
subtype,comparedtothat diagnosedindevelopedcountries.
Elucidation of etiology and predisposing factors to the
disease in Sub-Saharan women is likely to contribute to the
understanding of breast cancer in African-American patients
and, possibly, in other subsets of women with triple negative
disease.
Furthermore, the hypothesis of an infectious etiology of
breast cancerin Africa cannot be excluded.It was introduced
by the evidence of a relatively increased incidence of breast
cancer in men, compared to that observed in non-African
countries where it is a rare disease in males (P<0.05). For
instance, the male/female ratio in Tanzania is 1:14 (0.071),
similar to the overall ratio does in the majority of Sub-
Saharan African countries (0.0143; CI = 0.0317–0.877) [17].
In summary, although breast cancer incidence is lower in
Sub-Saharan African countries than in developed countries,
women tend to be diagnosed at a more advanced stage
than women in the developed world and are more likely to
die from it. Unfortunately, early detection of the disease is
hampered by limited awareness and understanding of the
disease even among health care professionals [18, 19].
In this regard, the experience of Sudan is instructive.
Sudan ﬁrst initiated a national cancer control program
(NCCP)in1982inassociationwiththeWorldHealthOrgan-
isation (WHO). This program focuses on prevention, early
detection, and screening, improved diagnosis and treatment,
and palliative care. Sudan has educational strategies for
both the general public and medical professionals to dispel
many of the misconceptions about cancer and promote early
detection and referral of cancer patients. Radio was selected
as an important medium in a country of low literacy rates.
To raise awareness amongst women about the importance
of self-examination for breast irregularities, a simple booklet
was produced and widely distributed [20].
3.Progress inBreast CancerinWestern
Countries:A RealityCheck
Breast cancer is the most costly disease in the US because of
its common incidence. About $16.5 billion are spent each
year in the US on breast cancer diagnosis and treatment.
When lost work productivity due to breast cancer for an
additional $12.1 billion is added, and about $2.5 billion for
breast cancer-speciﬁc peer-reviewed research is included,the
expenditure exceeds $31 billion/year [21].
A reasonable assessment of the results from this invest-
ment requires multiple measures of outcome with parame-
ters that span from a reduction in disease-speciﬁc mortality
to improvements in quality of life after diagnosis. Breast
cancer mortality is decreasing, and Berry et al. [22]h a v e
estimated that during the past ten years it has approximately
decreased 1% per year due to a combination of screening
and adjuvant treatment, both equally contributing to this
progress.
This pace of the yearly reduction of mortality, however,
has been questioned. It remains unclear whether this small
incremental progress could be sustained until eradication of
the disease, and it is certainly much too slow to be acceptable
to survivors, advocates, and many health care professionals
caring for breast cancer patients. In addition, the mortality
reduction has not been universal, with less progress in wom-
en under 50 and in African-American and Hispanic wom-
en. Moreover, the common use of mortality-over-incidence
ratio, as a measure of success in eradicating a disease, mayInternational Journal of Breast Cancer 3
overestimate the objective progress in breast cancer. This is
due to the fact that much of the increased incidence per-
tains to “trivial” cancers, mostly detected by mammography
screening, unlikely to represent a fatal hazard [23, 24].
Evidence has also emerged that at least some of these
mammography-detected cancers may spontaneously regress.
A change in the routine screening protocol in Norway
permitted this observation. In 1996, the Ministry of Health
and Care Services initiated the Norwegian Breast Cancer
Screening Program, in which women between the ages of 50
and64wereinvitedtoundergoatwo-viewbiennialscreening
mammography program. The women in this study who
make up the “screened” group thus underwent a ﬁrst round
of screening mammography in 1996-1997, a second round
in 1998-1999, and a third round in 2000-2001. Women
(age range 50–69 years) who would have been invited to
participate in the screening program between 1992 and 1997
hadtheNorwegianBreastCancerScreeningProgramexisted,
then, were studied as a “control group.” These women only
underwent one screening mammogram at the end of their
six-year period compared to the three mammograms the
women in the screened group underwent. The investigators
excluded carcinoma in situ (DCIS) and concentrated only
on invasive carcinoma. The screened group had 22% more
diagnoses of invasive carcinoma than the group that only
received one screening test at the end of a six-year period,
suggesting that approximately 1/5 of breast cancers may
regress spontaneously [23].
In summary, the breast cancer problem remains mainly
unsolved in Western countries, much in need of more eﬀec-
tive solutions if eradication is the target. Moreover, diﬀer-
ences of the disease in LMCs further temper any enthusiasm
to export our existing screening and treatment protocols.
4.DifferencesinMenopausal
Statusat Presentation
The incidence of breast cancer in Caucasian women in the
Western World peaks after menopause, whereas in the rest of
the world, it peaks before menopause [25]. A recent analysis
suggested that at least two types of breast cancer exist,
basedontheirclinicalcourse:rapidlyprogressing (diagnosed
before menopause, estrogen receptor (ER) negative, with a
poorprognosisand high mortality rate)and slowly progress-
ing (diagnosed after menopause, ER positive, with a good
prognosis and low mortality rate) [26, 27].
For example, nulliparity and obesity decrease breast can-
cer risk in younger women but is associated with increased
riskinolderwomen.High-grade,aggressive tumorsaremore
common in younger women, whereas low-grade tumors
are more common among the elderly, with bimodal peak
frequencies at ages 50 and 70, respectively. Curves depicting
the annual hazard of breast cancer death for women with
early-onset and late-onset tumors are shaped diﬀerently
and move in opposite directions [28]. In addition, mam-
mography screening and neoadjuvant chemotherapy seem
to have diﬀerent eﬀects in women with early and late-onset
tumors. Taken together, these qualitative age interactions
may indicate that early- and late-onset breast cancers are
likelytobediﬀerentdiseases,derivedfromdiﬀerentpathways
[28].
Applying these observations to the pattern of breast can-
cer observed in LMCs suggests that the rapidly progressing
type might be predominant in LMCs, as it is in young
Hispanic women [29], as opposed to the slowly progressing,
late-onset type more commonly observed in Caucasian
women from developed countries.
This hypothesis has several implications.
(1) Breast cancer in LMCs, young, and non-Caucasian
women might have a diﬀerent etiology than that
occurring in women from the Western world.
(2) Higher breast cancer mortality rates in LMCs young
and non-Caucasian women are only partly due to
patterns of care and lack of screening.
(3) Current approaches to screening may not be as eﬀec-
tive in these groups and should be reexamined from
this vantage point.
5.Mammography Screening:IstheWestern
WorldExperienceFeasible inLMCs?
In many Western countries, mammography screening for
earlydetectionofbreastcancerhasbecomeastandard ofcare
and the most common form fordisease detection.Despite its
widespread use, mammography is far from being a perfect
means of early detection. Several limitations have been rec-
ognized, particularly ifmammography screening isproposed
as a strategy for addressing the global breast cancer problem.
5.1. False Positive Results. In the US,an average of 11 percent
of screening mammograms is read as abnormal and neces-
sitates further diagnostic evaluation [30]. Breast cancer is
found in about 3 percent of women with an abnormal mam-
mogram (representing 0.3 percent of all mammograms).
Fletcher and Elmore demonstrated that, on average, a
woman has about a 10.7 percent chance of a false positive
result witheachmammogram [31].Awoman’srisk ofhaving
a false positive mammogram increases over time with re-
peated screenings. Elmore et al. [32] estimated that, after
10 mammograms, about half of women (49 percent) will
have had a false positive result, which would have led to an
unnecessary needle biopsy or an open biopsy in 19 percent
of screened women. Conversely, the false negative rate of 20–
26% [33] contributes to a false sense of security in some
women and it may result in delaying their time to diagnosis.
A Cochrane systematic review of six clinical trials involv-
ing half a million women concluded that mammography
screening resulted in an absolute risk reduction for mortality
of 0.05% and was associated with an absolute risk of over-
diagnosis of 0.5% [34]. This means that for every 2,000
women invited for screening over a 10-year period, one
woman will have her life prolonged, whereas 10 healthy
women will beoverdiagnosedand treatedunnecessarily [34].
These numbers are sobering and should be carefully consid-
ered before proposing to introduce mammography in LMCs.4 International Journal of Breast Cancer
5.2.AgeDistributionandBreast Cancer Screening. Mammog-
raphy is most eﬀective for detection of slow-growing tumors
in postmenopausal women, after age 50. In Western coun-
tries, mammography screening in women aged 40–49 years
has failed to result in a signiﬁcant reduction of breast cancer
mortality [35, 36]. A similar lack of eﬀect could be foreseen
in LMCs, where the majority of women are under the age of
50 and breast cancer tends to occur earlier. Interestingly, the
early mammography screening trials before the introduction
of adjuvant systemic therapy actually demonstrated an
increase in breast cancer mortality rates among women who
were aged less than 50 years at the start of those trials [37].
This has beenreferred toas a“mortality paradox”potentially
associated with the inadequate treatment of the early-onset
cancersor, possibly, a surgery-induced angiogenesis inbreast
cancer [38]. Since adjuvant treatment options are often
lacking or are not aﬀordable for many women in LMCs, it
is likely that the “mortality paradox” would be observed in
LMCs as well.
5.3. Ethnic and Biological Diﬀerences. Ethnic and biological
diﬀerencesmay further reducethe beneﬁt ofmammography.
For instance, women in many Asian LMCs typically have
smaller breast volumeand relatively dense parenchyma com-
pared to Caucasian women [39], both characteristics unsuit-
able for screening mammography.
5.4. Social and Cultural Barriers. Misconceptions associated
with biopsies triggered by screening mammography could
be particularly harmful in some LMCs, where a low level
of knowledge about cancer and the meaning of screening
prevail. For example, after a breast biopsy women and their
families could erroneously be “labeled” as cancer carriers
(even when the results are negative), resulting in social
stigmatizationandostracism withdramaticpsychosocialand
economic consequences. Serious ethical concerns emerge
with mammography screening in LMCs if followup and
treatment are not made availableor aﬀordableforthe major-
ity of women.
5.5. Harm-to-Beneﬁt Ratio. As mammography screening
programs are promoted around the world, the common
tendency is to emphasize the beneﬁts and deemphasize the
harms [40]. The harms of mammography screening consist
of false-positive ﬁndings resulting in anxiety for the woman
and her family, lack of aﬀordable treatment and followup,
overdiagnosis (detection of early lesions like DCIS, most of
which wouldneverhaveclinicallysurfaced in theindividual’s
lifetime), and false-negative exams. The harm-to-beneﬁt
ratio should be carefully considered prior to implementation
of mammography screening in LMCs. In the US, most
screened women tend to overestimate the beneﬁt of a
screening procedure [40], an issue amply debated in the UK
and other European countries [41].
5.6. Cost-Eﬀectiveness. Mammography screening programs
are expensive to initiate and sustain. The WHO Commission
on Macroeconomics and Health criteria has proposed that
a health intervention can be considered cost-eﬀective if it
achieves savings of one disability-adjusted life year for less
than three times of a country’s GDP [3, 42].
To date, very few studies addressed the cost-eﬀectiveness
of mammography screening in developing countries. Two
recent analyses of breast screening concluded that it is not
cost-eﬀective in countries like China [43]a n dI n d i a[ 44].
6.WesternTreatmentModel:Treatingthe Many
to Beneﬁt theFew
Therapeutic options derived from existing experiences may
also beasdisappointing. Forinstance, inWesternexperience,
the tumors most frequently detected by mammography are
those <2cm in size (tumor size T1), often treated by breast
conservation. In this subset, if no cancer cells are found in
the lymph nodes, survival 8 years after breast conservation
surgery and radiation is about 86%. Attempts to further
improve this rate require treating all to beneﬁt only a
few. Five years of tamoxifen treatment increases the overall
survival at 8 years from 86% to 93%; adding chemotherapy
results in a further gain of 2%, to a total of 95% at 8 years
[45]. Otherwise stated, 86 of 100 women with early breast
cancer will be alive and free of detectable disease 8 years
after surgical excision, regardless of any additional hormone
therapy or chemotherapy. If tamoxifen is added, 93 of 100
women will be alive at 8 years. Because 86 of those would
have been free of disease whether they were treated with
t a m o x i f e no rn o ta n d7w o u l dh a v ed i e d ,n e v e r t h e l e s s ,t h e
real beneﬁt is conﬁned to 7 women. As a result, 100 women
are treated to really beneﬁt only 7. The data is even more
sobering when chemotherapy is added, for every 100 women
receiving chemotherapy, only 2 will derive beneﬁt from this
additional treatment. Since chemotherapy can cause signiﬁ-
cant side eﬀects, deciding its use for this subset of patients is
diﬃcult in Western countries and even more so in LMCs.
7.Breast CancerinLMCs:ADifferentApproach
Instead of translating Western experience to LMCs, we pro-
pose that breast cancer in LMCs represents a unique oppor-
tunity to understand this disease and, at the same time, the
occasion to objectively reassess our progress. For instance,
original solutions to eﬀectively interfere with recurrence of
breast cancer in LMCs have already emerged [46, 47].
It is likely that more of these cost-eﬀective approaches
will emerge from local stakeholders, aware of the complex
reality of health delivery and care in their country. For
example, handheld ultrasound devices for on-site diagnosis
of palpable lesions could be operated by ancillary health
personnel. Well-designed prospective studies could identify
variables associated with successful detection and result
in an algorithm that enhances accuracy in distinguishing
malignant masses from benign ones. Insights about etiology
could be derived by studying associations of speciﬁc changes
in lifestyle and diet with the incidence of the disease. In
addition, new lessons about hospice and palliative care can
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development of speciﬁc guidelines for LMCs [49]a n do p e n
the way for novel interventions to be tested worldwide.
Since locally advanced breast cancer remains the most
common presentation of the disease worldwide, detection
and downstaging programs [50] focused on eﬀective treat-
ment may demonstrate more cost-eﬀective in LMCs than a
campaign for screening and early detection. Importantly, in
LMCs that have not introduced mammographic screening
for early detection, it is more likely for incidental cancers or
trivial cancers to remain undiagnosed and not contribute to
enhance the denominator of incident cancer cases. In such
a setting, an intervention that successfully reduces breast
cancer mortality is easier to assess, since the reduction of
breast cancermortality is a more reliable parameter to follow
progress. Introduction of novel therapeutics could reﬂect a
targeted approach, by limiting treatment to women who are
highlylikelytoderivesurvivaladvantagefromtheirresponse,
as already done in other diseases [51, 52].
Recent high-level meetings on noncommunicable dis-
eases, as part of the 66th session of the United Nations Gen-
eral Assembly, identiﬁed several priorities including raising
theawareness aboutcancerinLMCsandtomakethebestuse
of available resources to strike a balance among prevention,
detection, and therapy [53].
8.Summary
In conclusion, the emergence of evidence that breast cancer
inLMCs is distinctfrom its counterpartinWestern countries
discourages the introduction of widespread programs of
population screening. In settings with limited resources,
focusing on expensive programs to identify women who are
at risk will inevitably deprive resources to treat and poten-
tially cure the aﬀected individuals. Similarly, therapeutic
intervention should reﬂect the social and cultural speciﬁcity
of the country in question, a task best left to indigenous
health care providers. Importantly, LMCs could be spared by
the repetition of experiences that mainly failed in Western
countries.
Addressing the global challenge of breast cancer requires
a dispassionate reassessment of the progress Western coun-
tries have made, with a critical analysis of the current prac-
tices. In fact, the opportunities of studying breast cancer in
the rest of the world may provide us with much needed
insight about what we have missed, despite so much human
and ﬁnancial investment.
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